Zhejiang AngLiKang Pharmaceutical CO.,LTD. (002940.SZ)
CNY 13.82
(-0.22%)
CNY 13.82
(-0.22%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.62 Billion | 1.56 Billion | 1.38 Billion | 1.28 Billion | 1.39 Billion | 1.25 Billion |
| Cost of Revenue | 900.5 Million | 670.54 Million | 487.75 Million | 317.37 Million | 375.32 Million | 378.34 Million |
| Gross Profit | 725.35 Million | 897.88 Million | 892.61 Million | 972.27 Million | 1.02 Billion | 876.7 Million |
| Operating Expenses | 509.02 Million | 752.82 Million | 730.96 Million | 768.33 Million | 870.12 Million | 756.44 Million |
| Selling, General and Administrative Expenses | 350.98 Million | 576.37 Million | 646.37 Million | 724.23 Million | 810.74 Million | 678.34 Million |
| Research and Development Expenses | 143.36 Million | 112.62 Million | 52.55 Million | 43.87 Million | 37.34 Million | 46.2 Million |
| Other Expenses | -4.48 Million | 63.83 Million | 32.03 Million | 213.84 Thousand | 22.03 Million | 6.07 Million |
| Cost and Expenses | 1.4 Billion | 1.42 Billion | 1.21 Billion | 1.08 Billion | 1.24 Billion | 1.13 Billion |
| Operating Income | 211.68 Million | 148.55 Million | 174.17 Million | 211.68 Million | 155.1 Million | 131.23 Million |
| Interest Expense | 14.71 Million | 6.39 Million | 367.81 Thousand | 171.4 Thousand | 124.43 Thousand | 2.34 Million |
| Income Tax Expense | 24.13 Million | 14.95 Million | 31.32 Million | 29.44 Million | 27.23 Million | 15.64 Million |
| Earnings before Tax | 207.19 Million | 146.94 Million | 172.64 Million | 210.74 Million | 153.69 Million | 137.31 Million |
| Net Income | 138.37 Million | 127.29 Million | 119.84 Million | 163.71 Million | 112.26 Million | 108.69 Million |
| Earnings Per Share Basic | 0.69 | 0.64 | 0.61 | 0.86 | 0.59 | 0.73 |
| Earnings Per Share Diluted | 0.69 | 0.64 | 0.61 | 0.86 | 0.59 | 0.73 |
| Weighted Average Shares Outstanding | 200.53 Million | 198.47 Million | 197.39 Million | 190.17 Million | 189.22 Million | 149.37 Million |
| Weighted Average Shares Outstanding (Diluted) | 200.53 Million | 198.47 Million | 197.39 Million | 190.17 Million | 189.22 Million | 149.37 Million |
| Gross Margin | 0.45 | 0.57 | 0.65 | 0.75 | 0.73 | 0.70 |
| EBIT Margin | 0.18 | 0.14 | 0.16 | 0.20 | 0.14 | 0.13 |
| Profit Margin | 0.09 | 0.08 | 0.09 | 0.13 | 0.08 | 0.09 |
| EBITDA | 300.14 Million | 220.68 Million | 219.37 Million | 258.18 Million | 191.96 Million | 183.45 Million |
| Earnings Before Tax Margin | 0.13 | 0.09 | 0.13 | 0.16 | 0.11 | 0.10 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 270.88 Million | 435.9 Million | 407.99 Million | 438.88 Million | 1.62 Billion | 343.69 Million |
| Cost of Revenue | 187.95 Million | 246.83 Million | 245.86 Million | 253.41 Million | 900.5 Million | 208.39 Million |
| Gross Profit | 82.93 Million | 189.06 Million | 162.13 Million | 185.47 Million | 725.35 Million | 135.29 Million |
| Operating Expenses | 116.72 Million | 110.72 Million | 112.38 Million | 112.75 Million | 509.02 Million | 120.1 Million |
| Selling, General and Administrative Expenses | 54.68 Million | 63.13 Million | 69.29 Million | 37.1 Million | - | 92.78 Million |
| Research and Development Expenses | 62.54 Million | 47.71 Million | 49.08 Million | 44.82 Million | - | 44.35 Million |
| Other Expenses | -62.03 Million | 128.99 Thousand | -219.24 Thousand | -1.78 Million | -4.48 Million | -2.69 Million |
| Cost and Expenses | 304.67 Million | 357.55 Million | 358.24 Million | 366.16 Million | 1.4 Billion | 328.5 Million |
| Operating Income | -33.79 Million | 78.34 Million | 53.24 Million | 57.16 Million | 211.68 Million | 16 Million |
| Interest Expense | 3.62 Million | 4.98 Million | 4.75 Million | 3.91 Million | 14.16 Million | 4.1 Million |
| Income Tax Expense | -12.22 Million | 6.33 Million | 5.61 Million | 13.2 Million | 24.13 Million | -209.89 Thousand |
| Earnings before Tax | -29.67 Million | 83.92 Million | 53.02 Million | 55.38 Million | 207.19 Million | 13.31 Million |
| Net Income | -18.16 Million | 39.87 Million | 28.21 Million | 28.57 Million | 138.37 Million | 5.56 Million |
| Earnings Per Share Basic | -0.09 | 0.20 | 0.14 | 0.14 | - | 0.03 |
| Earnings Per Share Diluted | -0.09 | 0.20 | 0.14 | 0.14 | - | 0.03 |
| Weighted Average Shares Outstanding | 199.7 Million | 199.7 Million | 201.56 Million | 200.75 Million | 200.53 Million | 201.59 Million |
| Weighted Average Shares Outstanding (Diluted) | 199.7 Million | 199.7 Million | 201.56 Million | 200.75 Million | 200.53 Million | 201.59 Million |
| Gross Margin | 0.31 | 0.43 | 0.40 | 0.42 | 0.45 | 0.39 |
| EBIT Margin | -0.10 | 0.23 | 0.14 | 0.17 | - | 0.05 |
| Profit Margin | -0.07 | 0.09 | 0.07 | 0.07 | 0.09 | 0.02 |
| EBITDA | -26.05 Million | 101.46 Million | 55.87 Million | 74.57 Million | - | 18.38 Million |
| Earnings Before Tax Margin | -0.12 | 0.18 | 0.13 | 0.13 | 0.13 | 0.05 |
000659
5345
7731
FBVI
300313
JRVR